Pexidartinib

Major

Pexidartinib Omeprazole Gastrobim Explained Reduced pexidartinib exposure Details Pexidartinib Relugolix Orgovyx Explained Increased relugolix exposure Details Pexidartinib Acitretin Soriatane® Hepatotoxicity Details Pexidartinib Atogepant Qulipta Reduced atogepant exposure Details Pexidartinib Avapritinib Ayvakit Reduced avapritinib exposure and reduced efficacy of avapritinib Details Pexidartinib Cariprazine Vraylar Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Pexidartinib Aficamten Reduced aficamten exposure and reduced efficacy of aficamten Details Pexidartinib Amlodipine Amvaz® Reduced amLODIPine exposure Details Pexidartinib Bedaquiline Sirturo Reduced bedaquiline exposure and reduced efficacy of bedaquiline Details Pexidartinib Cabozantinib Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Pexidartinib Cabozantinib (Thyroid Cancer) Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Pexidartinib Cyclosporine Injection Atopica Increased cycloSPORINE exposure Details Pexidartinib Cyclosporine Ophthalmic Cequa Increased cycloSPORINE exposure Details Pexidartinib Cytarabine Cytosar-U® Hepatotoxicity Details Pexidartinib Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Pexidartinib Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Pexidartinib Dacarbazine DTIC-Dome® Hepatotoxicity Details Pexidartinib Danazol Danocrine® Hepatotoxicity Details Pexidartinib Deferasirox Exjade Hepatotoxicity Details Pexidartinib Dexlansoprazole Dexilant Reduced pexidartinib exposure Details Pexidartinib Digoxin Cardoxin® Increased digoxin exposure Details Pexidartinib Doravirine Pifeltro Reduced doravirine exposure and reduced efficacy of doravirine Details Pexidartinib Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Pexidartinib Esomeprazole Nexium Reduced pexidartinib exposure Details Pexidartinib Esomeprazole Injection Nexium Reduced pexidartinib exposure Details Pexidartinib Felbamate Felbatol Hepatotoxicity Details Pexidartinib Fentanyl Transdermal Patch Duragesic® Reduced exposure of fentaNYL, reduced efficacy of fentaNYL and/or onset of opioid withdrawal symptoms Details Pexidartinib Finerenone Kerendia Reduced finerenone exposure and reduced efficacy of finerenone Details Pexidartinib Flutamide Eulexin Hepatotoxicity Details Pexidartinib Gemtuzumab Ozogamicin Injection Mylotarg Hepatotoxicity Details Pexidartinib Ketoconazole Topical Extina® Foam Increased pexidartinib exposure; hepatotoxicity Details Pexidartinib Lansoprazole Prevacid Reduced pexidartinib exposure Details Pexidartinib Lefamulin Xenleta Altered (increased or reduced) lefamulin exposure, an increased risk of lefamulin-related adverse reactions and reduced efficacy o... Details Pexidartinib Leflunomide Arava Hepatotoxicity Details Pexidartinib Lenacapavir Injection Sunlenca Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Pexidartinib Lenacapavir Oral Sunlenca Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Pexidartinib Leniolisib Joenja Reduced leniolisib exposure and reduced efficacy of leniolisib Details Pexidartinib Letermovir Injection Prevymis Increased pexidartinib exposure Details Pexidartinib Levonorgestrel After banger Reduced levonorgestrel exposure and increased risk of breakthrough bleeding and/or contraceptive failure Details Pexidartinib Levonorgestrel Intrauterine System Kyleena Reduced levonorgestrel exposure and increased risk of breakthrough bleeding and/or contraceptive failure Details